ICU Medical (ICUI) reported strong Q3 earnings with a 9% growth in IV Systems business. New installations and strong census drove double-digit growth in LVP pumps and dedicated sets. The company is engaged in new RFP processes and discussions on Plum 360 refresh. FDA dialogue on new products continues.

The company is focused on sustained growth in the medium term by combining legacy ICU parts with acquired Smith components. Q3 was a record quarter due to delayed installs from Q2. The company is comfortable with mid-single-digit growth for the year. FDA dialogue on MedFusion 5000 and CATA ambulatory pumps is ongoing.

ICU Medical is working on improving gross margins and reducing debt. The company paid down $25 million in principal on its Term Loan B and completed a refinancing to save $2 million annually in interest expenses. Q4 guidance includes an increase in full-year EBITDA and adjusted EPS ranges. The company is confident in its financial performance and future growth prospects.

ICU Medical remains focused on driving value through competitive market share gains, refresh of installed base, and new revenue streams. The company is exploring potential portfolio management opportunities within its Vital Care segment. Q&A session addressed FDA dialogue, free cash flow, and potential strategic moves. Overall, ICU Medical is optimistic about its financial performance and growth potential.

Read more at Yahoo Finance: ICU Medical (ICUI) Q3 2025 Earnings Transcript